Next Article in Journal
Communication between B-Cells and Microbiota for the Maintenance of Intestinal Homeostasis
Next Article in Special Issue
Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases
Previous Article in Journal
Development of an Antibody for Detection of Rhamnolipids Characterized as a Major Bacterial Virulence Factor
Previous Article in Special Issue
Ricin and Ricin-Containing Immunotoxins: Insights into Intracellular Transport and Mechanism of action in Vitro
Article Menu

Export Article

Open AccessReview
Antibodies 2013, 2(3), 517-534; doi:10.3390/antib2030517

T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

Faculty of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel
*
Author to whom correspondence should be addressed.
Received: 15 August 2013 / Revised: 22 August 2013 / Accepted: 22 August 2013 / Published: 17 September 2013
(This article belongs to the Special Issue Recombinant Immunotoxins)
View Full-Text   |   Download PDF [215 KB, uploaded 17 September 2013]

Abstract

Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable target for novel immunotherapeutic approaches. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, most TCRs produced thus far have affinities which are too low for target detection under normal assay conditions, and limited stability (due to their generation in a single-chain version). Developing high-affinity soluble antibody molecules endowed with a TCR-like specificity toward tumor epitopes, termed TCR-like antibodies, addresses the low affinity of TCRs. These TCR-like antibodies are being developed as a new immunotherapeutic class for targeting tumor cells and mediating their specific killing. In addition, these antibodies are valuable research reagents enabling the study of human class I peptide-MHC ligand-presentation and TCR–peptide–MHC interactions. View Full-Text
Keywords: antibodies; antibody engineering; immunotoxins; MHC-peptide complex; phage display; recombinant antibodies; T-cell receptor; cancer immunotherapy antibodies; antibody engineering; immunotoxins; MHC-peptide complex; phage display; recombinant antibodies; T-cell receptor; cancer immunotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Cohen, M.; Reiter, Y. T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. Antibodies 2013, 2, 517-534.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top